Published Technical Disclosure Archive

Next-Generation Ocular Delivery Systems

Publication ID: 24-11857460_0005_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Ocular Delivery Systems,” Published Technical Disclosure No. 24-11857460_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857460_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,460.

Summary of the Inventive Concept

Envisioning a paradigm shift in ocular delivery systems, this concept combines cutting-edge technologies such as nanofluidics, artificial intelligence, bioresorbable materials, and machine learning to revolutionize the treatment of glaucoma and other eye disorders.

Background and Problem Solved

The original patent disclosed systems and methods for accessing Schlemm's canal, delivering a fluid composition, and performing a trabeculotomy. However, these systems have limitations in terms of precision, efficacy, and personalized treatment. The new inventive concept addresses these limitations by introducing advanced technologies that enable targeted, real-time, and adaptive ocular delivery.

Detailed Description of the Inventive Concept

The next-generation ocular delivery systems comprise a nanofluidic device integrated with an AI-powered navigation system to optimize fluid flow and pressure within Schlemm's canal. The system can be combined with bioresorbable micro-devices that release controlled amounts of therapeutic agents over predetermined periods. Additionally, wearable sensor arrays and machine learning-based analytics platforms can provide real-time monitoring of ocular pressure and fluid flow, enabling predictive and preventive glaucoma treatment. The systems can also be personalized through genetic profiling and 3D-printed customized implants.

Novelty and Inventive Step

The new claims introduce a fundamental shift in ocular delivery systems by incorporating AI, nanofluidics, bioresorbable materials, and machine learning. These advancements enable unprecedented precision, adaptability, and personalized treatment, making the original patent's concepts obsolete.

Alternative Embodiments and Variations

Alternative embodiments may include using different types of AI algorithms, integrating the systems with other medical devices, or developing implantable sensors for continuous monitoring. Variations may include using different materials, shapes, or sizes for the nanofluidic devices or bioresorbable micro-devices.

Potential Commercial Applications and Market

The next-generation ocular delivery systems have vast commercial potential in the ophthalmology and pharmaceutical industries, with potential applications in treating glaucoma, cataracts, and other eye disorders. The market for these systems is expected to grow significantly as the technology advances and becomes more widely adopted.

CPC Classifications

SectionClassGroup
A A61 A61F9/0008
A A61 A61F9/00781
A A61 A61M5/002
A A61 A61M5/158
A A61 A61M5/3286
A A61 A61M5/3291
A A61 A61M2005/1585
A A61 A61M2210/0612

Field of Art

Ophthalmic medical devices and methods for ocular fluid management, specifically focused on interventional techniques for glaucoma treatment and Schlemm's canal manipulation

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or medical device specialist with expertise in microsurgical technologies, fluidic systems, and ophthalmological interventional techniques, possessing knowledge of advanced medical device design, fluid delivery mechanisms, and minimally invasive surgical approaches

Obviousness Rationale

A PHOSITA would recognize that the PTD's proposed variations represent predictable technological extensions of the source patent's core ocular delivery system, leveraging known techniques in medical device miniaturization, AI-assisted navigation, and personalized therapeutic approaches. The fundamental mechanism of accessing and manipulating Schlemm's canal remains consistent, with the PTD introducing incremental technological enhancements that would be considered obvious improvements to an existing ocular delivery system.

Obvious Combinations & Variations

Source Patent Element
Cannula-based fluid delivery system for accessing Schlemm's canal
PTD Variation
Nanofluidic device with AI-powered navigation system for optimizing fluid flow
Obviousness Reasoning
Predictable application of advanced control technologies to existing fluid delivery mechanisms, representing a known technique of integrating intelligent guidance systems into medical devices
Source Patent Element
Linear gear and linkage mechanism for fluid delivery control
PTD Variation
Bioresorbable micro-devices with controlled therapeutic agent release
Obviousness Reasoning
Obvious design modification using known biomaterial technologies to enhance the original fluid delivery concept with targeted, time-released therapeutic capabilities
Source Patent Element
Method of advancing a cannula into an eye for fluid delivery
PTD Variation
Robotic-assisted micro-robotic device for precise trabeculotomy and canal navigation
Obviousness Reasoning
Predictable technological progression applying robotic precision to existing minimally invasive surgical techniques, representing a finite and obvious solution for improving surgical accuracy
Source Patent Element
Fluid composition delivery into Schlemm's canal
PTD Variation
Personalized treatment using genetic profiling and 3D-printed customized implants
Obviousness Reasoning
Known approach of personalizing medical interventions through genetic analysis and advanced manufacturing techniques, representing an obvious extension of standard medical device design principles
Source Patent Element
Elongate member for fluid delivery within a cannula
PTD Variation
Wearable sensor array with machine learning-based analytics for ocular pressure monitoring
Obviousness Reasoning
Predictable integration of sensor technologies and data analytics into existing medical device frameworks, representing a standard approach to enhancing diagnostic capabilities
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857460 and the disclosed technological variations, a person having ordinary skill in the art would find the proposed ocular delivery system innovations obvious and lacking inventive step. The incremental technological enhancements represented in the published technical disclosure constitute prima facie obviousness under 35 U.S.C. ยง 103, as they represent predictable applications of known medical device design principles to existing ocular intervention technologies.

Original Patent Information

Patent NumberUS 11,857,460
TitleOcular delivery systems and methods
Assignee(s)Sight Sciences, Inc.